Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
NEW YORK - Immunic, Inc. (NASDAQ: IMUX), a biotechnology firm focused on developing treatments for chronic inflammatory and autoimmune diseases, has launched a public offering of warrants. The company, currently valued at $87.48 million, has seen its stock decline nearly 29% over the past year according to InvestingPro data. This offering includes pre-funded warrants, as well as Series A and Series B warrants to purchase common stock, with expiration dates of December 31, 2025, and five years post-issuance, respectively. The specific terms and potential size of the offering are contingent on market conditions and other factors.
The company plans to channel the net proceeds from this offering into its clinical trials and general corporate functions. This funding comes at a crucial time, as InvestingPro analysis shows Immunic is quickly burning through cash, with a current ratio of 0.74 indicating short-term obligations exceed liquid assets. Leerink Partners is the sole bookrunner for the offering, which is made pursuant to a shelf registration statement effective since May 31, 2024.
Immunic’s pipeline features vidofludimus calcium (IMU-838) in phase 3 trials for relapsing multiple sclerosis, with expected top-line data by the end of 2026. While analyst price targets range from $5 to $28, suggesting significant upside potential, InvestingPro reports 8 additional key insights about the company’s financial health and growth prospects. Additionally, IMU-856 is being developed to potentially treat various gastrointestinal diseases, and IMU-381 is in preclinical testing for gastrointestinal conditions.
This press release contains forward-looking statements and does not constitute an offer to sell or a solicitation of an offer to buy any securities. The offering is subject to registration or qualification under the securities laws of any state or jurisdiction.
The information in this article is based on a press release statement from Immunic, Inc.
In other recent news, Immunic, Inc. reported encouraging phase 2 trial results for its drug candidate vidofludimus calcium in treating progressive multiple sclerosis (PMS). The CALLIPER trial demonstrated a 20% reduction in the risk of disability worsening over 24 weeks compared to a placebo, with notable benefits observed in primary progressive multiple sclerosis (PPMS) patients. These findings were shared alongside a webcast discussion, highlighting the drug’s potential neuroprotective effects and confirming its safety and tolerability profiles. In another development, Immunic announced a registered direct offering of its common stock, pricing 5,666,667 shares at $0.90 each, aiming to raise approximately $5.1 million. The proceeds are intended to support clinical trials, operations, and general corporate purposes, with Aberdeen Investments leading the offering. Additionally, William Blair initiated coverage on Immunic with an Outperform rating, citing the potential of vidofludimus calcium in relapse-remitting multiple sclerosis (RMS) therapy. The analyst emphasized the drug’s superior safety profile and its potential to disrupt the oral RMS therapy market. These recent developments underscore Immunic’s ongoing progress in advancing treatments for multiple sclerosis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.